MAIA Biotechnology (MAIA) director receives 25,206 stock options exercisable at $1.53

Rhea-AI Filing Summary

MAIA Biotechnology director reports new stock option grant

A MAIA Biotechnology, Inc. director filed a Form 4 disclosing a grant of stock options on December 31, 2025 under the company’s 2021 Equity Incentive Plan. The grant covers 25,206 stock options, each giving the right to buy one share of MAIA common stock at an exercise price of $1.53 per share. These options vest 100% on the grant date and are exercisable beginning that same day, with an expiration date of December 31, 2035. Following this grant, the reporting person holds 25,206 derivative securities directly, all in the form of these options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Luput Cristian

(Last) (First) (Middle)

444 WEST LAKE STREET, SUITE 1700

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options	$1.53	12/31/2025		A		25,206		12/31/2025(1)	12/31/2035	Common Stock	25,206	$0	25,206	D

Explanation of Responses:

1. The stock options, granted on December 31, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

	/s/ Cristian Luput	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MAIA (MAIA) disclose in this Form 4?

MAIA Biotechnology disclosed that a director received a grant of 25,206 stock options to purchase common stock on December 31, 2025 under the 2021 Equity Incentive Plan.

What is the exercise price and term of the new MAIA (MAIA) stock options?

The stock options have an exercise price of $1.53 per share and an expiration date of December 31, 2035, giving the director the right to purchase common shares until that date.

When do the MAIA (MAIA) options granted on December 31, 2025 vest and become exercisable?

The options vest 100% on the grant date of December 31, 2025 and are exercisable beginning as of that date, according to the explanation of responses.

How many MAIA (MAIA) derivative securities does the reporting person own after this transaction?

After the reported grant, the director beneficially owns 25,206 derivative securities, all stock options, held in direct ownership.

Under which plan were the MAIA (MAIA) stock options granted?

The stock options were granted pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, as stated in the explanation of responses.

What is the role of the reporting person at MAIA (MAIA)?

The reporting person is identified as a Director of MAIA Biotechnology, Inc., as indicated in the relationship section.